Human IgG-F(ab')2 Fragment Cross-Adsorbed Antibody



Antibody		
F(ab')2 Goat Pol	lyclonal	I Conjugate HRP
Antigen Affinity Purified		
Catalog No.	A80-24	49P
Lot No.	18	
APPLICATIONS		WB, IHC, ICC, ELISA
SPECIES REACTIVITY		Human. Minimum reactivity to mouse and rat
AMOUNT		1 ml
CONCENTRATION	N	0.5 mg/ml
STORAGE/SHELF	LIFE	2 - 8°C / 1 year from date of receipt
PHYSICAL STATE		Liquid
BUFFER		Phosphate Buffered Saline (PBS) containing 0.2% BSA and 0.05% Pro-Clean 400
ISOTYPE		IgG
ORIGIN		USA
PRODUCTION PROCEDURES		Antiserum was solid phase adsorbed to ensure specificity. Antiserum was cross adsorbed using mouse and rat immunosorbents to remove cross reactive antibodies. The antibody to human F(ab')2 was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab')2 fragments were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed. Fragments were conjugated to horseradish peroxidase (HRP).
		Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
		By immunoelectrophoresis and ELISA this antibody reacts specifically with human F(ab')2. No antibody was detected against non-immunoglobulin serum proteins. Less than 1% cross reactivity to mouse and rat IgG was detected. This antibody may cross react with F(ab')2 from other species.
APPLICATIONS		Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.
		Western Blot1:2,000 - 1:20,000Immunohistochemistry1:200 - 1:2,000Immunocytochemistry1:200 - 1:2,000ELISA1:10,000 - 1:50,000
APPLICATION NO	OTES	Not all listed applications have been specifically tested by our laboratory.
ADDITIONAL INFO	0	https://www.fortislife.com/p/A80-249P Use the link above to view SDS, a current list of citations, and other product specific information.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Michael Spencer, PhD Date: October 30, 2023

1